Literature DB >> 12877677

Basic fibroblast growth factor-stimulated ex vivo expansion of haematopoietic progenitor cells from human placental and umbilical cord blood.

Ikuo Kashiwakura1, Tsuneo A Takahashi.   

Abstract

We investigated whether basic fibroblast growth factor (bFGF) is effective in inducing ex vivo expansion of CD34+ haematopoietic progenitor cells derived from human placental and umbilical cord blood. bFGF significantly promoted the clonal growth of various haematopoietic progenitor cells, including granulocyte-macrophage colony-forming units (CFU-GM), mixed colony-forming units (CFU-Mix) and megakaryocyte colony-forming units (CFU-Meg) under semisolid culture conditions, with an optimal bFGF concentration of 30 ng/ml. CD34+ cells were then cultured in serum-free liquid medium containing various combinations of early-acting cytokines, including thrombopoietin (TPO), stem cell factor (SCF), interleukin 3 (IL-3) and flt3-ligand (FL), with or without bFGF, for 6 and 12 d. Without bFGF, TPO + IL-3, TPO + SCF + FL and TPO +SCF + IL-3 + FL dramatically increased the total numbers of erythroid progenitors, CFU-GM and CFU-Mix by d 12 of culture respectively. However, the addition of bFGF did not promote further proliferation of these progenitors, except for the erythroid progenitors, by d 6 when stimulated with all four cytokines. In contrast, total CFU-Meg numbers were approximately doubled when these cultures were supplemented with bFGF, producing 100- to 120-fold increases compared with the baseline control cultures. These results suggest that bFGF is effective in supporting the generation of megakaryocytic progenitor cells during ex vivo expansion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877677     DOI: 10.1046/j.1365-2141.2003.04444.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes.

Authors:  Nathalie Rosenblatt-Velin; Mario G Lepore; Cristina Cartoni; Friedrich Beermann; Thierry Pedrazzini
Journal:  J Clin Invest       Date:  2005-06-09       Impact factor: 14.808

2.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

3.  Human cardiac stem cells isolated from atrial appendages stably express c-kit.

Authors:  Jia-Qiang He; Duc Minh Vu; Greg Hunt; Atul Chugh; Aruni Bhatnagar; Roberto Bolli
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

4.  Characteristics of human CD34+ cells exposed to ionizing radiation under cytokine-free conditions.

Authors:  Junya Ishikawa; Naoki Hayashi; Masaru Yamaguchi; Satoru Monzen; Ikuo Kashiwakura
Journal:  J Radiat Res       Date:  2015-04-15       Impact factor: 2.724

5.  Application of proteoglycan extracted from the nasal cartilage of salmon heads for ex vivo expansion of hematopoietic progenitor cells derived from human umbilical cord blood.

Authors:  Ikuo Kashiwakura; Kenji Takahashi; Keiichi Takagaki
Journal:  Glycoconj J       Date:  2007-03-28       Impact factor: 3.009

Review 6.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.